Skip to main content
$0.007 0.001 (16.67%)

High

$0.01

Low

$0.01

Trades

19

Turnover

$1,131

Volume

188,484
30 June 2023 at 4:10pm
Register to track ATH and receive email alerts.

Short Interest

ASIC data, 19 Aug 2026

% Shorted

0.00%
vs 0.00% prior report

Most Shorted Rank

604th
of 704 shorted ASX stocks

Peak Short

1.18%
Jan 2024

Days to Cover

0.0
at 50d avg vol
Subject
ATH Ann: Notice of Annual General Meeting/Proxy Form

ATH Ann: Presentation of New Biomarker Data at Scientific Congress

ATH Ann: Form 20-F

ATH Ann: ATH filed Form 20-F and XBRL data with SEC

ATH Ann: Change in substantial holding

ATH Ann: Appendix 4G and Corporate Governance Statement 2021

ATH Ann: Appendix 4E & Annual Report 2021

ATH Ann: Change in substantial holding

ATH Ann: New US Patent Expands Neurodegeneration Treatment Portfolio

ATH Ann: Appendix 4C and Quarterly Cash Flow Report

ATH Ann: New Publication Demonstrates ATH434 is Neuroprotective

ATH Ann: Change in substantial holding

ATH Ann: Change in substantial holding

ATH Ann: Change in substantial holding

ATH Ann: Change in substantial holding

ATH Ann: Change in substantial holding

ATH Ann: Notice under section 708A(5) of the Corporations Act

ATH Ann: Application for quotation of securities - ATH

ATH Ann: Proposed issue of securities - ATH

ATH Ann: New US patent targeting major neurodegenerative diseases

ATH Ann: Change in substantial holding

ATH Ann: EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial

ATH Ann: Investor Presentation

ATH Ann: Alterity to present at MST Access Investor Conference

ATH Ann: Appendix 4C and Quarterly Cash Flow Report

ATH Ann: Change in substantial holding

ATH Ann: Ceasing to be a substantial holder

ATH Ann: ATH434 protects brain cells and improves motor function

ATH Ann: Appendix 3G

ATH Ann: Change in substantial holding

ATH Ann: Alterity to present at Global Life Science Conference

ATH Ann: Change in substantial holding

ATH Ann: Alterity to present at 7th International Congress of MSA

ATH Ann: Half Yearly Report and Accounts

ATH Ann: Change in substantial holding

ATH Ann: Alterity Half Year Results and Investor Webcast Notification

ATH Ann: Change in substantial holding

ATH Ann: Change in substantial holding

ATH Ann: Change in substantial holding

ATH Ann: Change in substantial holding

ATH Ann: Appendix 2A and Section 708A(5) Cleansing Notice

ATH Ann: Change in substantial holding

ATH Ann: Proposed issue of Securities - ATH

ATH Ann: Michael J Fox grant for Parkinson's research on ATH434

ATH Ann: Appendix 4C and Quarterly Cash Flow Report

ATH Ann: Change in substantial holding

ATH Ann: Alterity participates in JP Morgan healthcare conference

ATH Ann: Dr David Stamler Appointed CEO

ATH Ann: Change in substantial holding

ATH Ann: Form F-3

Register to track ATH and receive email alerts.

Similar Companies

CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX